210 related articles for article (PubMed ID: 36343646)
1. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Mayer-Hamblett N; Ratjen F; Russell R; Donaldson SH; Riekert KA; Sawicki GS; Odem-Davis K; Young JK; Rosenbluth D; Taylor-Cousar JL; Goss CH; Retsch-Bogart G; Clancy JP; Genatossio A; O'Sullivan BP; Berlinski A; Millard SL; Omlor G; Wyatt CA; Moffett K; Nichols DP; Gifford AH;
Lancet Respir Med; 2023 Apr; 11(4):329-340. PubMed ID: 36343646
[TBL] [Abstract][Full Text] [Related]
2. The cost of simplifying treatments for cystic fibrosis: Implications of the SIMPLIFY trial.
Gold LS; Hansen RN; Mayer-Hamblett N; Nichols DP; Gifford AH; Kloster M; Goss CH; Kessler L
J Manag Care Spec Pharm; 2024 Jan; 30(1):26-33. PubMed ID: 38153868
[TBL] [Abstract][Full Text] [Related]
3. Dornase alfa for cystic fibrosis.
Yang C; Montgomery M
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001127. PubMed ID: 33735508
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
5. Challenges in the treatment of cystic fibrosis in the era of CFTR modulatorsAuthors' replyUse of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele a systematic review and meta-analysisDiscontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY) results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsAssessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.
Schmidt CJ; Moura LS; Dalcin PTR; Ziegler B
J Bras Pneumol; 2024 May; 50(2):e20240107. PubMed ID: 38808835
[No Abstract] [Full Text] [Related]
6. Dornase alfa for cystic fibrosis.
Yang C; Montgomery M
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001127. PubMed ID: 30187450
[TBL] [Abstract][Full Text] [Related]
7. Dornase alfa for cystic fibrosis.
Yang C; Chilvers M; Montgomery M; Nolan SJ
Cochrane Database Syst Rev; 2016 Apr; 4():CD001127. PubMed ID: 27043279
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer AZ; MacGregor G; Azevedo P; Indihar V; Keating C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Rubenstein RC; Taylor-Cousar JL; Tullis E; Yonker LM; Chu C; Lam AP; Nair N; Sosnay PR; Tian S; Van Goor F; Viswanathan L; Waltz D; Wang LT; Xi Y; Billings J; Horsley A; ;
Lancet Respir Med; 2023 Jun; 11(6):550-562. PubMed ID: 36842446
[TBL] [Abstract][Full Text] [Related]
9. Inhaled mannitol for cystic fibrosis.
Nolan SJ; Thornton J; Murray CS; Dwyer T
Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
[TBL] [Abstract][Full Text] [Related]
10. The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study.
Donaldson SH; Corcoran TE; Pilewski JM; Laube BL; Mogayzel P; Ceppe A; Wu J; Zeman K; Rowe SM; Nichols DP; Gifford AH; Bennett WD; Mayer-Hamblett N;
J Cyst Fibros; 2024 May; 23(3):457-460. PubMed ID: 38355350
[TBL] [Abstract][Full Text] [Related]
11. Inhaled mannitol for cystic fibrosis.
Nevitt SJ; Thornton J; Murray CS; Dwyer T
Cochrane Database Syst Rev; 2020 May; 5(5):CD008649. PubMed ID: 32358807
[TBL] [Abstract][Full Text] [Related]
12. Inhaled mannitol for cystic fibrosis.
Nevitt SJ; Thornton J; Murray CS; Dwyer T
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD008649. PubMed ID: 29424930
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design.
Mayer-Hamblett N; Nichols DP; Odem-Davis K; Riekert KA; Sawicki GS; Donaldson SH; Ratjen F; Konstan MW; Simon N; Rosenbluth DB; Retsch-Bogart G; Clancy JP; VanDalfsen JM; Buckingham R; Gifford AH
Ann Am Thorac Soc; 2021 Aug; 18(8):1397-1405. PubMed ID: 33465316
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
16. Dornase alfa for cystic fibrosis.
Jones AP; Wallis C
Cochrane Database Syst Rev; 2010 Mar; (3):CD001127. PubMed ID: 20238314
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
18. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
19. Nebulised hypertonic saline for cystic fibrosis.
Wark P; McDonald VM
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001506. PubMed ID: 30260472
[TBL] [Abstract][Full Text] [Related]
20. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial.
Ratjen F; Davis SD; Stanojevic S; Kronmal RA; Hinckley Stukovsky KD; Jorgensen N; Rosenfeld M;
Lancet Respir Med; 2019 Sep; 7(9):802-809. PubMed ID: 31178421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
